Understanding the Part D spending dynamics of heart failure patients

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Bruce S. Pyenson, Gabriela Dieguez, Mark Koransky | 18 May 2017

Understanding pharmacy spending by heart failure (HF) patients requires an evaluation of the complex interactions between members, payers, and manufacturers in Part D. Part D spending by HF patients is higher than for other patients due to their condition and related comorbidities. The portions of spending attributable to the member, pharmaceutical manufacturer, Part D plan, and federal government can vary dramatically.

This report was commissioned by Novartis Pharmaceuticals Corporation.

Authors